Carperitide?Acetate(alpha-humanatrialnatriureticpeptide) , 10mMinWater , 89213-87-6

CAS NO.：89213-87-6

Empirical Formula: C127H203N45O39S3

Molecular Weight: 3080.44

MDL number: MFCD00076226

EINECS: 686-482-9

PRODUCT Properties

• Density: 1.55±0.1 g/cm3(Predicted)
• storage temp.: Store at -20°C
• solubility: Water: 1 mg/ml
• form: A lyophilized powder
• Sequence: H-Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Met-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr-OH，(Disulfide bridge: Cys-Cys)
• InChIKey: NSQLIUXCMFBZME-VUEHYBQXNA-N

Description and Uses

Carperitide is the α-human atrial natriuretic peptide (α-hANP) produced by recombinant technology. It was introduced in Japan as a treatment for acute congestive heart failure (CHF). In dogs with CHF, carperitide significantly reduced the elevated left ventricular end-diastolic pressure and the index of myocardial oxygen consumption (systolic blood pressure x heart rate). In a clinical trial, carperitide was effective in improving hemodynamics and symptoms in 60% of patients with acute CHF. Carperitide was reported to be well tolerated with no significant adverse effects clinically. A beneficial effect on hemodynamics has been reported in chronic heart failure patients. Carperitide is also in clinical trials for maintenance of blood pressure during surgical operations.

Treatment of decompensated congestive heart failure.

Safety

• Symbol(GHS): GHS08
• Signal word: Warning
• Hazard statements: H361
• Precautionary statements: P201-P202-P281-P308+P313-P405-P501